Related Experiment Video

Updated: Feb 19, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.6K

Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a

Giovanni Ferrandi1,2, Greta Bagnolini1, Laura Poppi2

  • 1Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.

ACS Medicinal Chemistry Letters
|February 18, 2026
PubMed

Insights

Researchers developed a novel compound that induces synthetic lethality in BRCA2-functional pancreatic cancer cells. This compound sensitizes cancer cells to PARP inhibitors, offering a potential new strategy for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Synthetic lethality is a promising strategy for anticancer drug combinations.
  • Targeting the BRCA2 and PARP pathway offers a synthetic lethal approach.
  • BRCAness phenotype can sensitize cancer cells to PARP inhibitors.

Purpose of the Study:

  • To develop small molecule inhibitors of RAD51-BRCA2 interaction.
  • To create compounds that induce the BRCAness phenotype.
  • To identify synergistic drug combinations for pancreatic cancer treatment.

Main Methods:

  • Design and synthesis of phenyl furan-carboxyquinoline analogues.
  • Evaluation of RAD51-BRCA2 protein-protein interaction inhibition.
  • Assessment of homologous recombination impairment and synthetic lethality induction.

Main Results:

  • Compound 19 effectively inhibits RAD51-BRCA2 interaction.
  • Compound 19 impairs homologous recombination.
  • Compound 19 synergizes with olaparib in BxPC-3 pancreatic cancer cells, inducing synthetic lethality in 2D and 3D models.
  • Compound 19 demonstrates efficacy in human pancreatic cancer cells with no toxicity in normal cells.

Conclusions:

  • Compound 19 is a potent inhibitor of RAD51-BRCA2 interaction.
  • Compound 19 serves as a valuable tool compound for further research and optimization.
  • This approach holds potential for developing novel pancreatic cancer therapies.
Keywords:
RAD51-BRCA2Synthetic lethalitypancreatic cancerprotein−protein interaction inhibitorssmall molecules

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.4K